Current Status: Site-Specific Antibody Drug Conjugates
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as diverse aspects as antibody engineering, chemical linker optimization and novel conjugation strategies, together aiming at constantly widening the therapeutic window for ADCs. This review primarily focuses on novel chemical and biotechnological strategies for the site-directed attachment of drugs that are currently validated for 2nd generation ADCs to promote conjugate homogeneity and overall stability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adding New Chemistries to the Genetic Code
Liu, C. C., & Schultz, P. G. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.105824 · Cited by 1,725 · cited 1×
“Moreover, many different unnatural amino acids have successfully been incorporated to proteins by this method and one can choose from a broad selection of substrates increasing chemical flexibility [30].”
BackgroundAntibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Novel antibody-antibiotic conjugate eliminates intracellular S. aureus
Lehar, S. M., Pillow, T., Xu, M., Staben, L., Kajihara, K. K., Vandlen, R., DePalatis, L., Raab, H., Hazenbos, W. L., Hiroshi Morisaki, J., et al. (2015) · Nature · doi:10.1038/nature16057 · Cited by 838 · cited 1×
“This particularly includes pathogens that have previously been hard or impossible to tackle, as has recently been exemplified for novel Antibody-antibiotic conjugates targeting well-hidden, intracellular populations of pathogenic bacteria [62].”
BackgroundImplications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372 · cited 1×
“unnatural sialic acid derivatives [40, 41].”
Cited by
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Nanobodies: Chemical Functionalization Strategies and Intracellular Applications
Schumacher, D., Helma, J., Schneider, A. F. L., Leonhardt, H., & Hackenberger, C. P. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708459 · Cited by 260
Self-citationGlycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Metadata
- Authors
- Schumacher, D., Hackenberger, C. P. R., Leonhardt, H., & Helma, J.
- Venue
- Journal of Clinical Immunology
- Published
- 2016-03-22
- Volume
- 36
- Issue
- S1
- Pages
- 100-107
- ISSN
- 0271-9142 (ISSN-L)
- 1573-2592
- OpenAlex
- W2309076462
- Cited by
- 144
- References
- 4
- FWCI
- 18.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Status: Site-Specific Antibody Drug Conjugates. https://app.cochat.ai/papers/10.1007/s10875-016-0265-6
- The paper
- Schumacher, D., Hackenberger, C. P. R., Leonhardt, H., & Helma, J. (2016). Current Status: Site-Specific Antibody Drug Conjugates. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-016-0265-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.